Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in Acute Myeloid Leukemia (AML): A retrospective multicenter study on behalf of the EHA AML-specialized working group (SWG)

View Full Paper
Ask AI
Bookmark
Share

Authors

EFEmiliano FabianiFRFrancesca RomanoGOGuadalupe Oñate

Discussion

Loading...

Member takes

Overview

Retrospective multicenter study shows FLT3-ITD microclones are linked to older age in acute myeloid leukemia, suggesting further randomized trials on treatment implications.

Key Points

  • Patients with FLT3-ITD microclones were older, showing significant clinical implications for treatment strategies.
  • The study used capillary electrophoresis to analyze FLT3-ITD status and found a notable prognostic impact of microclones.
  • Overall survival at 3 years was 58% in intensively treated acute myeloid leukemia patients, indicating treatment effectiveness.
  • The presence of FLT3-ITD microclones calls for further investigation into tailored therapeutic options in clinical trials.

Cite This Study

Fabiani et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc4chttps://doi.org/10.1182/blood-2025-217
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of initial FLT3-ITD mutated clone numbers on clinical outcomes in Acute Myeloid Leukemia2025
  2. 2Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: Insights from real-world genomic data2025
  3. 3Prognostic factors for newly diagnosed Acute Myeloid Leukemia with FLT3-TKD - a multicenter retrospective study2025
  4. 4DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors2025 · 2 citations
  5. 5Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation2025 · 1 citations